0000899243-20-018864.txt : 20200709 0000899243-20-018864.hdr.sgml : 20200709 20200709201836 ACCESSION NUMBER: 0000899243-20-018864 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200708 FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PENG STANFORD L CENTRAL INDEX KEY: 0001711352 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 201021544 MAIL ADDRESS: STREET 1: C/O ALPINE IMMUNE SCIENCES, INC. STREET 2: 201 ELLIOTT AVE. WEST, SUITE 230 CITY: SEATTLE STATE: WA ZIP: 98119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-08 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001711352 PENG STANFORD L C/O ALPINE IMMUNE SCIENCES, INC. 188 EAST BLAINE STREET, SUITE 200 SEATTLE WA 98102 0 1 0 0 See Remarks Stock Option (right to buy) 7.20 2020-07-08 4 A 0 50000 0.00 A 2029-04-21 Common Stock 50000 50000 D The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. On April 22, 2019, the reporting person was granted an Option to purchase 50,000 shares of Common Stock. The shares underlying the Option vest and are exercisable upon the satisfaction of certain performance criteria. On July 8, 2020, the Issuer's board of directors determined that the performance criteria for the shares underlying the Option were satisfied, resulting in all of the shares of Common Stock underlying the Option being fully vested and exercisable. President & Head of Research and Development /s/ James Paul Rickey, attorney-in-fact 2020-07-09